[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595061":3},{"organization":4,"outcomesModule":7,"designInfo":59,"detailedDescription":58,"studyPopulation":58,"armGroups":65,"interventions":76,"overallOfficials":58,"centralContacts":86,"locations":92,"responsibleParty":105,"collaborators":58,"id":109,"slug":58,"hasResults":110,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":110,"sex":116,"minAge":117,"maxAge":118,"enrollmentInfo":119,"targetDuration":58,"studyType":122,"phases":123,"briefSummary":125,"conditions":126,"keywords":129,"overallStatus":135,"whyStopped":58,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":140,"completionDateStruct":141,"leadSponsor":143,"locationsCount":144},{"fullName":5,"class":6},"University of Bath","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":58},[9],{"measure":10,"description":11,"timeFrame":12},"Weekly minutes of moderate-vigorous physical activity","Measured using a Geneactiv wrist-based activity monitor","Baseline and 8 weeks",[14,17,20,22,25,28,31,34,37,40,43,46,49,52,55],{"measure":15,"description":16,"timeFrame":12},"Body mass index","kg\u002Fm2",{"measure":18,"description":19,"timeFrame":12},"Waist circumference","Measured in centimetres",{"measure":21,"description":19,"timeFrame":12},"Waist to hip ratio",{"measure":23,"description":24,"timeFrame":12},"1-minute sit to stand test","Participant stands up and sits down from a chair for one minute and the number of completed sit-to-stands is recorded.",{"measure":26,"description":27,"timeFrame":12},"Multidimensional Fatigue Inventory","Measured on 20 questions with a scale of 1-5. The maximum possible score is 100 with a higher score indicating more acute levels of fatigue",{"measure":29,"description":30,"timeFrame":12},"Cystic Fibrosis Questionnaire Revised","Quality of life questionnaire validated for Cystic Fibrosis. Scores range from 0 to 100, with higher scores indicating better health.",{"measure":32,"description":33,"timeFrame":12},"Manchester Musculoskeletal Screening tool","Musculoskeletal pain questionnaire. A higher score indicates a worse outcome. Maximum possible score is 50, minimum possible score is 0",{"measure":35,"description":36,"timeFrame":12},"Sleep quality","3-day sleep quality and quantity diary",{"measure":38,"description":39,"timeFrame":12},"Fasting insulin levels, pmol\u002FL","Taken from the early morning fasted capillary blood sample",{"measure":41,"description":42,"timeFrame":12},"Fasting triglyceride concentration, mmol\u002FL","Taken with the early morning fasted capillary blood sample",{"measure":44,"description":45,"timeFrame":12},"Serum fructosamine, mmol\u002FL","Taken from the fasted early morning capillary blood sample",{"measure":47,"description":48,"timeFrame":12},"Fasting LDL-C, HDL-C and total cholesterol, mmol\u002FL","Taken from the fasted early morning capillary blood samples",{"measure":50,"description":51,"timeFrame":12},"High sensitivity C-reactive protein, mg\u002FL","Measured in the capillary blood samples taken",{"measure":53,"description":54,"timeFrame":12},"Forced expiratory volume in one second","Obtained by spirometry. Recorded as litres per minute and percentage predicted values using Global Lung Index reference values",{"measure":56,"description":57,"timeFrame":12},"Forced Vital Capacity","Obtained through spirometry. Recorded as litres per minute and percentage predicted values using Global Lung Index reference values.",null,{"allocation":60,"interventionModel":61,"interventionModelDescription":58,"primaryPurpose":62,"observationalModel":58,"timePerspective":58,"maskingInfo":63},"RANDOMIZED","PARALLEL","PREVENTION",{"masking":64,"maskingDescription":58,"whoMasked":58},"NONE",[66,71],{"label":67,"type":68,"description":58,"interventionNames":69},"Intervention","EXPERIMENTAL",[70],"Behavioral: Mobile health exercise programme",{"label":72,"type":73,"description":58,"interventionNames":74},"Control","ACTIVE_COMPARATOR",[75],"Other: Lifestyle maintenance",[77,82],{"type":78,"name":79,"description":80,"armGroupLabels":81,"otherNames":58},"BEHAVIORAL","Mobile health exercise programme","8 week personalised exercise intervention. Delivered and monitored via mobile health technology",[67],{"type":6,"name":83,"description":84,"armGroupLabels":85,"otherNames":58},"Lifestyle maintenance","Continue current lifestyle",[72],[87],{"name":88,"role":89,"phone":90,"phoneExt":58,"email":91},"Rachel C McDowell","CONTACT","01225 388 388","rcm76@bath.ac.uk",[93],{"facility":94,"status":58,"city":95,"state":58,"zip":96,"country":97,"countryCode":98,"cosmosGeoPoint":99,"geoPoint":104,"contacts":58},"Centre for Nutrition, Exercise and Metabolism","Bath","BA2 7AY","United Kingdom","UK",{"type":100,"coordinates":101},"Point",[102,103],-2.36172,51.3751,{"lat":103,"lon":102},{"type":106,"investigatorFullName":107,"investigatorTitle":108,"investigatorAffiliation":5,"oldNameTitle":58,"oldOrganization":58},"PRINCIPAL_INVESTIGATOR","Rachel McDowell","GW4-CAT PhD Programme for Health Professionals PhD Programme Fellow","100595061",false,"NCT07027553","Remote Exercise to Improve Physical Activity Levels and Markers of Heart Health in Cystic Fibrosis (RHH-CF)","A Research Study to Understand Whether Remote Exercise Can Improve Physical Activity Levels and Markers of Heart Health in Cystic Fibrosis","RHH-CF","Inclusion Criteria:\n\n* Past diagnosis of Cystic Fibrosis confirmed via two copies of a faulty CFTR gene, or; previous sweat chloride test with a result \\>60mmol\u002FL chloride, or; prescribed modulator therapy (Orkambi, Symkevi, Kaftrio);\n\nExclusion Criteria:\n\n* Any reported condition, behaviour or reported use of substances which may pose undue personal risk to the participant or introduce bias into the study, except for any which are ubiquitous in society and so would be equally distributed between groups and\u002For therefore relevant to generalisation (e.g. caffeine)\n* Medications which increase risk of harm to a participant exercising remotely such as fluoroquinolone antibiotics, beta blockers, or blood pressure medication\n* Individuals with unstable or poorly controlled diabetes\n* Individuals on statins\n* Females who are pregnant or lactating\n* Individuals with a previous self-reported history of an eating disorder\n* Individuals unable to provide informed consent e.g. inability to read or speak English\n* Individuals who are not weight stable (i.e. \\>3kg change in body mass in the past 3 months)\n* Individuals awaiting a solid organ transplant, have a diagnosis of pulmonary hypertension or require long term oxygen therapy to exercise at home\n* Individuals with chest pain, dizziness or loss of consciousness during exercise, who have been instructed by a doctor to only do certain types\u002Fquantity of physical activity\n* Individuals on any current ongoing medication or treatment for injuries or illness which impact on their ability to do physical tasks or exercises\n* Individuals who are PAR-Q positive response during screening","ALL","18 Years","65 Years",{"count":120,"type":121},30,"ESTIMATED","INTERVENTIONAL",[124],"NA","With advances in genetic therapies, many people with Cystic Fibrosis (CF) are living longer. With the improvement in life expectancy has emerged an increased risk of cardiovascular disease (CVD). Factors such as insulin resistance, reduced physical activity, rising blood pressure from newer medications, and changes in body mass index have made cardiovascular health a growing concern in CF care.\n\nThis study aims to assess whether a remotely delivered, monitored exercise programme can increase physical activity levels in adults with CF. Secondary outcomes will explore whether the intervention improves key CVD risk factors. Participants will be randomly assigned to either a control group or an intervention group, which will complete an 8-week home-based aerobic and resistance exercise programme. Exercise intensity will be tailored using the Rate of Perceived Exertion scale.\n\nKey outcomes include weekly physical activity levels, body mass index, waist circumference, lung function (spirometry) and blood biomarkers. Home-based capillary blood tests, analysed pre- and post-intervention, will measure cholesterol, lipid profiles, inflammation and other relevant hormones.",[127,128],"Cystic Fibrosis (CF)","Cardiovascular Disease Risk Factors",[130,131,132,133,134],"Exercise","Physical activity","Cystic Fibrosis","Cardiovascular disease risk","Mobile health interventions","NOT_YET_RECRUITING","2025-06-19",{"date":138,"type":139},"2025-06-25","ACTUAL",{"date":136,"type":121},{"date":142,"type":121},"2026-09-19",{"name":5,"class":6},1]